Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339018 | 0.94 | MAPT (0.57) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL4336228 | 0.90 | MAPT (0.49) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL4349234 | 0.85 | CCR5 (0.44) | MAPTSMN1; SMN2CCR5 | |
| SCHEMBL4351231 | 0.85 | MAPT (0.57) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL16570126 | 0.84 | MAPT (0.60) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL15244306 | 0.83 | MAPT (0.55) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL27624515 | 0.82 | MAPT (0.52) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL594885 | 0.81 | MAPT (0.60) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL4338080 | 0.80 | TP53 (0.40) | CCR5TP53 | |
| SCHEMBL30773887 | 0.78 | GPR119 (0.41) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740576-B1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-7211576-B2 | Diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1740576-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. Hoffman-la Roche AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103034-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. HOFFMAN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239843-A1 | Diaminothiazoles | DING QINGJIE | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239843-A1 | Diaminothiazoles | CDK4, CDK2, CDK1 | MAPT 1975/4885ALDH1A1 762/4885LMNA 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.